Certificate of Analysis for NR-52394

Vector pCAGGS Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Gene (soluble, stabilized)

Catalog No. NR-52394

This reagent is the tangible property of the U.S. Government.

Product Description:

The vector for the spike (S) glycoprotein gene from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: MN908947) was designed for expression of a soluble S glycoprotein with a polybasic cleavage site deletion (RRAR to A; residues 682 to 685) and stabilizing mutations (K986P and V987P, wild type numbering) with a C-terminal thrombin cleavage site, T4 foldon trimerization domain and hexa-histidine tag. The S sequence was codon optimized for mammalian expression and subcloned into the pCAGGS mammalian expression vector. NR-52394 contains the beta-lactamase gene, *bla*, to provide transformant selection through ampicillin resistance in *Escherichia coli (E. coli)*. Lot 70038122 was produced from a preparation of glycerol stock (NRC-52394 lot 70034724), grown in Luria-Bertani broth with ampicillin (50 µg per mL) for 1 day at 37°C in an aerobic atmosphere, extracted using a Plasmid *Plus* Maxi Kit (QIAGEN® 12963) and vialed in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

Lot: 70038122 **Manufacturing Date: 07AUG2020**

TEST	SPECIFICATIONS	RESULTS
Next-Generation DNA Sequencing[1]	~ 8530 base pairs	8537 base pairs
Genotypic Analysis[1] Sequencing of S glycoprotein insert (~ 3770 base pairs)	≥ 99% sequence identity to depositor's sequence Thrombin protease site sequence confirmed T4 foldon trimerization domain sequence confirmed His_6 tag sequence confirmed	100% sequence identity to depositor's sequence[2] Thrombin protease site sequence confirmed T4 foldon trimerization domain sequence confirmed His_6 tag sequence confirmed
Antibiotic Resistance Ampicillin (encoded by beta-lactamase gene *bla*)[3]	*bla* sequence present	*bla* sequence present
Agarose Gel Electrophoresis Digestion with *Sca*I	~ 6 kb and ~ 3 kb	~ 6 kb and ~ 3 kb (Figure 1)
Concentration by Picogreen® Measurement	≥ 2 µg/mL	0.1 µg in 20 µL per vial (6.8 µg/mL)
Amount per Vial	Report results	0.1 µg per vial
OD_{260}/OD_{280} Ratio (pre-vial)	1.7 to 2.1	2.0
Effective Bacterial Transformation Invitrogen™ One Shot™ TOP10 *E. coli*	≥ 50 colonies per ng	> 500 colonies per ng

[1]This test was performed pre-vial on a previous lot of extracted material (NR-52394 lot 70034717). The complete plasmid sequence and map are provided on the BEI Resources webpage.
[2]The NR-52394 insert was codon optimized for mammalian expression with mutations for stability and solubility, but otherwise is consistent with the SARS-CoV-2, Wuhan-Hu-1 S protein (GenPept: QHD43416).
[3]The antibiotic ampicillin degrades quickly during growth. Bacterial stationary phase should be minimized during plasmid expansion to avoid plasmid loss and increased antibiotic concentrations may be necessary.

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52394

Figure 1: Agarose Gel of Undigested and Restriction Enzyme Digested NR-52394



Lane 1: Invitrogen™ TrackIt™ 1 Kb Plus DNA Ladder
Lane 2: NR-52394 digested
Lane 3: NR-52394 undigested

/Heather Couch/
Heather Couch 27 AUG 2020
Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® and the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898